Read about CCNet in these publications:
Current Limitations and Future Prospects for Applying Systems Biology in Drug Discovery and the Clinic
Apic G, Russell RB.
Bioworld Europe, 3, 13-15, 2007
"Most Systems Biology scenarios advocate the use of data recently delivered by post-genomic technologies (microarrays, proteomics, etc.), but it is also important to consider data generated during the past decades of molecular biology, biochemistry, pharmaceutical and clinical research. The technical challenge is to somehow combine data sources as diverse as the scientific literature, DNA microarrays, high-throughput screens, toxicology studies or clinical trials to make usable predictive systems."
Read more
CCNet features in Genetic Engineering News
Omics: Toxicogenomics Enhances Drug Discovery
Working Toward Improving Hazard Identification and Risk Assessment
by Kathy Liszewski
"...Harnessing the power of computational modeling of biological pathways can help decipher molecular mechanisms of toxicity, according to Gordana Apic, Ph.D., CEO, Cambridge Cell Networks (www.camcellnet.com). "One of the biggest challenges in drug discovery today is understanding the molecular mechanisms of drug actions and mechanistic toxicity. Our company provides a series of products for elucidating mechanisms of toxicity. We use a multidisciplinary approach integrating bioinformatics, genomics and proteomics, chemistry, text mining, and mathematics." The company provides databases and core softwares. For example, they offer a manually curated database of more than 25,000 chemical structures..."
Read more
Illuminating drug discovery with biological pathways
Apic G, Ignjatovic T, Boyer S, Russell RB.
FEBS Lett. 2005 Mar 21;579(8):1872-7.
"...One of the biggest challenges in drug discovery today is the high attrition rate: many promising candidates prove ineffective or toxic owing to a poor understanding of the molecular mechanisms of biological systems they target. A "systems" approach can help identify pathways related to a disease and can suggest secondary effects of drugs that might cause these problems and thus ultimately improve the drug discovery pipeline..."
Read more
|
|
Our colaborative efforts with CCNet have been stimulating and fruitful and we look forward to continued success.
Head of Drug Discovery Informatics, Major Pharmaceutical Company
|
|
Case Studies